Yangyihua Zhou

Beijing, 100850, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Physics-Informed Artificial Intelligence Design of Picomolar Nanobodies Enables Deep Tumor Penetration and High-Contrast Imaging.

Physics-Informed Artificial Intelligence Design of Picomolar Nanobodies Enables Deep Tumor Penetration and High-Contrast Imaging.

Journal: Research (Washington, D.C.)

Published: February 27, 2026

A high-affinity CEA-targeted nanobody for 68Ga PET imaging and 177Lu-based radioisotope therapy: preclinical and first-in-human evaluation.

A high-affinity CEA-targeted nanobody for 68Ga PET imaging and 177Lu-based radioisotope therapy: preclinical and first-in-human evaluation.

Journal: Journal of nanobiotechnology

Published: September 11, 2025

Comparative evaluation of bispecific antibody formats targeting PD-1 and LAG-3 for dual checkpoint blockade in cancer immunotherapy.

Comparative evaluation of bispecific antibody formats targeting PD-1 and LAG-3 for dual checkpoint blockade in cancer immunotherapy.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: June 28, 2025

Clostridium perfringens alpha toxin drives pathological NETosis via immature neutrophil mobilization and functional reprogramming.

Clostridium perfringens alpha toxin drives pathological NETosis via immature neutrophil mobilization and functional reprogramming.

Journal: Acta pharmaceutica Sinica. B

Published: May 22, 2025

Reshaping antivenom therapy: A triple-synergy strategy featuring broadly neutralizing antibodies and a small-molecule PLA2 inhibitor.

Reshaping antivenom therapy: A triple-synergy strategy featuring broadly neutralizing antibodies and a small-molecule PLA2 inhibitor.

Journal: Acta pharmaceutica Sinica. B

Published: May 13, 2025

Novel Quaternary Ammonium Salt-Linked STING Agonist Antibody-Drug Conjugate: Synergistic Activation of Tumor Immunity with Mitigated Off-Target Toxicity.

Novel Quaternary Ammonium Salt-Linked STING Agonist Antibody-Drug Conjugate: Synergistic Activation of Tumor Immunity with Mitigated Off-Target Toxicity.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: February 06, 2025

Development and Characterization of 4A7: A High-Affinity Monoclonal Antibody Targeting Claudin18.2.

Development and Characterization of 4A7: A High-Affinity Monoclonal Antibody Targeting Claudin18.2.

Journal: ImmunoTargets and therapy

Published: September 22, 2024

Detection of TNF-α using the established ab-MPs-CLIA.

Detection of TNF-α using the established ab-MPs-CLIA.

Journal: Talanta

Published: August 25, 2024

Broad-Spectrum Engineered Multivalent Nanobodies Against SARS-CoV-1/2.

Broad-Spectrum Engineered Multivalent Nanobodies Against SARS-CoV-1/2.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: March 21, 2024

The application of Interleukin-2 family cytokines in tumor immunotherapy research.

The application of Interleukin-2 family cytokines in tumor immunotherapy research.

Journal: Frontiers in immunology

Published: November 05, 2022

Anti-Claudin18.2-IL-21 fusion protein bifunctional molecule has more powerful anti-tumor effect and better safety.

Anti-Claudin18.2-IL-21 fusion protein bifunctional molecule has more powerful anti-tumor effect and better safety.

Journal: International immunopharmacology

Published: October 12, 2022

PD-1/LAG-3 bispecific antibody potentiates T cell activation and increases antitumor efficacy.

PD-1/LAG-3 bispecific antibody potentiates T cell activation and increases antitumor efficacy.

Journal: Frontiers in immunology

Published: September 18, 2022

Showing 1-12 of 14

Last Updated: 09/26/2026